chr17-43082403-C-T
Variant summary
Our verdict is Pathogenic. Variant got 22 ACMG points: 22P and 0B. PVS1PM2PP3_StrongPP5_Very_Strong
The NM_007294.4(BRCA1):c.4357+1G>A variant causes a splice donor change. The variant allele was found at a frequency of 0.00000186 in 1,613,594 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 6.8e-7 ( 0 hom. )
Consequence
BRCA1
NM_007294.4 splice_donor
NM_007294.4 splice_donor
Scores
4
2
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 3.70
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 22 ACMG points.
PVS1
?
Splicing variant, LoF is a know mechanism of disease, No cryptic splice site detected. Exon removal results in frameshift change.
PM2
?
Very rare variant in population databases, with high coverage;
PP3
?
Splicing scoreres supports a deletorius effect: Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF, max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.
PP5
?
Variant 17-43082403-C-T is Pathogenic according to our data. Variant chr17-43082403-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 37584.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr17-43082403-C-T is described in Lovd as [Pathogenic]. Variant chr17-43082403-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
BRCA1 | NM_007294.4 | c.4357+1G>A | splice_donor_variant | ENST00000357654.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
BRCA1 | ENST00000357654.9 | c.4357+1G>A | splice_donor_variant | 1 | NM_007294.4 | P4 |
Frequencies
GnomAD3 genomes ? AF: 0.0000131 AC: 2AN: 152156Hom.: 0 Cov.: 32
GnomAD3 genomes
?
AF:
AC:
2
AN:
152156
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251154Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135750
GnomAD3 exomes
AF:
AC:
1
AN:
251154
Hom.:
AF XY:
AC XY:
0
AN XY:
135750
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461320Hom.: 0 Cov.: 30 AF XY: 0.00000138 AC XY: 1AN XY: 726870
GnomAD4 exome
AF:
AC:
1
AN:
1461320
Hom.:
Cov.:
30
AF XY:
AC XY:
1
AN XY:
726870
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? AF: 0.0000131 AC: 2AN: 152274Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74460
GnomAD4 genome
?
AF:
AC:
2
AN:
152274
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74460
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
?
AF:
AC:
1
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:23
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 1 Pathogenic:11
Pathogenic, criteria provided, single submitter | clinical testing | Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge | Oct 02, 2015 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | Oct 18, 2012 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine | Jul 31, 2017 | This c. 4357+1G>A (also known as IVS13+1G>A) variant in the BRCA1 gene has been reported in multiple patients with breast cancer from two families breast cancer patients (PMID15533909, PMID21769658). In the first family, The first patientthe proband was diagnosed at 30 years of age and with three female relatives of the proband were diagnosed with breast cancer before age 40 (PMID 5533909). The second patient in the second family was diagnosed at 26 years of age without with no known family history (PMID21769658). In silico analysis and experimental studies suggest that this variant causes exon 13 skipping (PMID24667779,21735045, 21769658). A multifactorial likelihood algorithm also predicts this variant to be deleterious (PMID 17924331). Based on the current evidence, this c. 4357+1G>A variant in the BRCA1 gene is classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA1) | May 29, 2002 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jul 11, 2023 | The BRCA1 c.4357+1G>A variant results in a substitution at the consensus splice donor site. A functional study conducted in patient cells demonstrated that this variant results in abnormal splicing which is predicted to result in a frameshift and premature termination of translation, leading to nonsense mediated mRNA decay (PMID: 21769658). Across a selection of the available literature, this variant has been identified in more than ten individuals with breast or ovarian cancer, including 5% of African American patients in a multi-center cohort (PMID: 21769658; PMID: 27425403; PMID: 29446198; PMID: 30322717; PMID: 31825140). This variant has also been detected in an individual with prostate cancer (PMID: 29368341). This variant is reported in the Genome Aggregation Database in one allele at a frequency of 0.000046 in the European (Finnish) population This variant has been classified as pathogenic by at least three submitters in ClinVar. Based on the available evidence, the c.4357+1G>A variant has been classified as pathogenic for hereditary breast and ovarian cancer. - |
Pathogenic, criteria provided, single submitter | clinical testing | Michigan Medical Genetics Laboratories, University of Michigan | Apr 21, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Oct 05, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Oct 21, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Counsyl | May 25, 2016 | - - |
Pathogenic, reviewed by expert panel | curation | Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) | Aug 10, 2015 | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on posterior probability = 0.9999 - |
Pathogenic, criteria provided, single submitter | clinical testing | Pathway Genomics | Oct 30, 2014 | - - |
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Jun 01, 2020 | The variant disrupts a canonical splice site, and is therefore predicted to result in the loss of a functional protein. Found in at least one patient with expected phenotype for this gene, and found in general population data at a frequency that is consistent with pathogenicity. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 20, 2022 | Canonical splice site variant demonstrated to result skipping of exon 12 which is predicted to result in a null allele in a gene for which loss-of-function is a known mechanism of disease (Thomassen 2012, Steffensen 2014); Observed in individuals with BRCA1-related cancers (Pal 2004, Thomassen 2012, Couch 2015, Pal 2015, Alemar 2016, Frey 2017, Delgado-Balderas 2018, Isaacsson Velho 2018); Multifactorial studies suggest this variant is associated with breast and ovarian cancer (Easton 2007, Lindor 2012); Classified as pathogenic by a well-established clinical consortium and/or database (ClinVar); Also known as 4476+1G>A (IVS13+1G>A); This variant is associated with the following publications: (PMID: 17924331, 30787465, 21735045, 15533909, 26287763, 24013928, 24797986, 20838878, 19241424, 25920394, 27425403, 25085752, 25525159, 28495237, 28476184, 25452441, 20104584, 26295337, 29368341, 28918466, 29997359, 26681312, 29907814, 30702160, 29446198, 30720243, 30322717, 21769658, 24667779, 33646313, 31447099, 31825140, 21990134) - |
Pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Oct 11, 2021 | The BRCA1 c.4357+1G>A variant (rs80358027), also known as IVS13+1G>A, is reported in the literature in multiple individuals affected with breast and/or ovarian cancer (Alemar 2016, Carter 2018, Pal 2004, Thomassen 2012). This variant is found on a single chromosome in the Genome Aggregation Database (1/251154 alleles), indicating it is not a common polymorphism. This variant abolishes the canonical splice acceptor site of intron 13, which is likely to disrupt gene function. Consistent with this, RNA analyses from a patient carrying this variant demonstrate skipping of exon 13, leading to a frameshift (Thomassen 2012). Based on available information, this variant is considered to be pathogenic. References: Alemar B et al. Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations. Cancer Genet. 2016 Sep;209(9):417-422. PMID: 27425403. Carter NJ et al. Germline pathogenic variants identified in women with ovarian tumors. Gynecol Oncol. 2018 Dec;151(3):481-488. PMID: 30322717. Pal T et al. BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1794-9. PMID: 15533909. Thomassen M et al. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Res Treat. 2012 Apr;132(3):1009-23. PMID: 21769658. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 06, 2019 | - - |
Hereditary breast ovarian cancer syndrome Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 27, 2017 | Variant summary: The BRCA1 c.4357+1G>A variant involves the alteration of a conserved intronic nucleotide located at the canonical splicing site. One in silico tool predicts a damaging outcome for this variant. 5/5 splice prediction tools predict that this variant abolishes the 5' splicing donor site. These predictions have been confirmed by RT-PCR showing that it leads to skipping of exon 12 (legacy exon 13) and frameshift p.Arg1397TyrfsX2 (Thomassen_2011). This variant was found in 1/121252 control chromosomes at a frequency of 0.0000082, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005). It has also been reported in multiple HBOC patients. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 10, 2020 | The c.4357+1G>A variant (also known IVS13+1G>A) in BRCA1 has been reported in >30 individuals with breast, ovarian or other associated cancers and segregated with disease in 3 affected individuals from 1 family (Pal 2004 PMID: 15533909, Couch 2015 PMID:25452441, Susswein 2016 PMID: 26681312, Tihomirova 2014 PMID: 24797986, Thomassen 2012 PMID: 21769658, Isaacsson 2018 PMID: 29368341, Alemar 2016 PMID: 27425403, Carter 2018 PMID: 30322717, Akbari 2014 PMID:23458327). It has also been identified in 0.005% (1/21620) of Finnish chromosomes by gnomAD (http://gnomad.broadinstitute.org). This variant was classified as Pathogenic on August 10, 2015 by the ClinGen-approved Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) expert panel (Variation ID 37584). This variant occurs within the canonical splice site (+/- 1,2) and is predicted to cause altered splicing leading to an abnormal or absent protein. Loss of function of the BRCA1 gene is an established disease mechanism in autosomal autosomal dominant HBOC. Multifactorial likelihood algorithm using genetic, in silico, and statistical data determined to have a high probability of being pathogenic (Easton 2007 PMID: 17924331, Lindor 2012 PMID: 21990134, Pruss 2014 PMID: 25085752). Experimental studies have shown that this variant causes exon 12 skipping in BRCA1 (Steffensen 2014 PMID: 24667779, Thomassen 2012 PMID: 21769658). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant HBOC. ACMG/AMP Criteria applied: PS4, PVS1_Strong, PM2, PM5, PS3_Supporting. - |
Pathogenic, no assertion criteria provided | research | Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto | Jan 31, 2014 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Dec 01, 2023 | This sequence change affects a donor splice site in intron 12 of the BRCA1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs80358027, gnomAD 0.004%). Disruption of this splice site has been observed in individual(s) with breast cancer (PMID: 15533909, 20104584, 24013928, 24797986, 25085752, 25452441, 26681312). This variant is also known as IVS13+1G>A. ClinVar contains an entry for this variant (Variation ID: 37584). Based on a multifactorial likelihood algorithm using genetic, in silico, and/or statistical data, this variant has been determined to have a high probability of being pathogenic (PMID: 17924331). Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 21735045, 21769658, 24667779; Invitae). For these reasons, this variant has been classified as Pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jun 13, 2022 | This variant causes a G to A nucleotide substitution at the +1 position of intron 12 of the BRCA1 gene. RNA studies have reported this variant to cause the out-of-frame skipping of exon 12 in carrier RNA and in minigene splicing assay (PMID: 21769658, 24667779 ), resulting in an unstable mRNA transcript (PMID: 21769658). This variant has been observed in multiple individuals and families affected with breast and ovarian cancer (PMID: 15533909, 20104584, 21769658, 23458327, 24797986, 25452441, 27425403, 30322717) and prostate cancer (PMID: 29368341). This variant has been identified in 1/251154 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | curation | Sema4, Sema4 | Apr 19, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 25, 2023 | The c.4357+1G>A intronic variant results from a G to A substitution one nucleotide after exon 12 (coding exon 11) of the BRCA1 gene. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. This allele was reported in one heterozygous individual in population-based cohorts in the Genome Aggregation Database (gnomAD). This mutation has been reported in multiple individuals with personal and/or family history consistent with hereditary breast and ovarian cancer (HBOC) syndrome (Pal, 2004; Akbari, 2014; Tihomirova, 2014; Couch, 2015; Alemar, 2016; Rebbeck, 2018). Functional analyses have demonstrated that this alteration leads to a skipping of coding exon 11 (also known as exon 13), causing a frameshift and alternate stop codon (Ambry internal data; Thomassen, 2012). In addition, this alteration has been classified as pathogenic (p>0.99) by multifactorial analysis, which integrates the following lines of evidence to produce a quantitative likelihood of pathogenicity: in silico prediction models, segregation with disease, tumor characteristics, mutation co-occurrence (Easton, 2007; Lindor, 2012; Vallee, 2012). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. Based on the available evidence, this alteration is classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
Cadd
Pathogenic
Dann
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
D;D;D;D;D;D;D;D;D;D;D;D;D;D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DL_spliceai
Position offset: 1
Find out detailed SpliceAI scores and Pangolin per-transcript scores at